Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.

Pagni F, Guerini-Rocco E, Schultheis AM, Grazia G, Rijavec E, Ghidini M, Lopez G, Venetis K, Croci GA, Malapelle U, Fusco N.

Int J Mol Sci. 2019 Nov 1;20(21). pii: E5452. doi: 10.3390/ijms20215452. Review.

2.

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.

Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E.

Cancers (Basel). 2019 Oct 24;11(11). pii: E1641. doi: 10.3390/cancers11111641.

3.

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.

Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2019 Sep 19. pii: jclinpath-2019-206127. doi: 10.1136/jclinpath-2019-206127. [Epub ahead of print]

PMID:
31537627
4.

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F.

Clin Transl Oncol. 2019 Aug 20. doi: 10.1007/s12094-019-02198-5. [Epub ahead of print]

PMID:
31432394
5.

Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.

Beca F, Lee SSK, Pareja F, Da Cruz Paula A, Selenica P, Ferrando L, Gularte-Mérida R, Wen HY, Zhang H, Guerini-Rocco E, Rakha EA, Weigelt B, Reis-Filho JS.

Histopathology. 2019 Dec;75(6):931-937. doi: 10.1111/his.13962. Epub 2019 Oct 13.

PMID:
31361912
6.

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F.

Clin Transl Oncol. 2019 Jun 28. doi: 10.1007/s12094-019-02166-z. [Epub ahead of print] Erratum in: Clin Transl Oncol. 2019 Aug 20;:.

PMID:
31254252
7.

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.

Fumagalli C, Catania C, Ranghiero A, Bosi C, Viale G, de Marinis F, Barberis M, Guerini-Rocco E.

J Clin Med. 2019 Jan 18;8(1). pii: E112. doi: 10.3390/jcm8010112.

8.

Liver toxicity in the era of immune checkpoint inhibitors: A practical approach.

Belli C, Zuin M, Mazzarella L, Trapani D, D'Amico P, Guerini-Rocco E, Achutti Duso B, Curigliano G.

Crit Rev Oncol Hematol. 2018 Dec;132:125-129. doi: 10.1016/j.critrevonc.2018.09.019. Epub 2018 Oct 3. Review.

PMID:
30447917
9.

Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.

Invernizzi M, Corti C, Lopez G, Michelotti A, Despini L, Gambini D, Lorenzini D, Guerini-Rocco E, Maggi S, Noale M, Fusco N.

BMC Cancer. 2018 Sep 29;18(1):935. doi: 10.1186/s12885-018-4851-2.

10.

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.

Fumagalli C, Guerini-Rocco E, Vacirca D, Passaro A, Marinis F, Barberis M.

Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027. No abstract available.

PMID:
30185137
11.

Letter to the Editor.

Fumagalli C, Casadio C, Barberis M, Guarize J, Guerini-Rocco E.

Clin Lung Cancer. 2018 Jul;19(4):e439-e440. doi: 10.1016/j.cllc.2018.03.001. Epub 2018 Mar 12. No abstract available.

PMID:
29606366
12.

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.

Breast Cancer Res Treat. 2018 Jul;170(2):351-360. doi: 10.1007/s10549-018-4767-1. Epub 2018 Mar 27.

PMID:
29589138
13.

Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.

Guerini-Rocco E, Passaro A, Casadio C, De Luca VM, Guarize J, de Marinis F, Vacirca D, Barberis M.

Arch Pathol Lab Med. 2018 Apr;142(4):465-473. doi: 10.5858/arpa.2017-0158-RA. Review.

PMID:
29565206
14.

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.

Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.

PMID:
29535211
15.

Looking for sputum biomarkers in lung cancer secondary prevention: where are we now?

Fusco N, Fumagalli C, Guerini-Rocco E.

J Thorac Dis. 2017 Nov;9(11):4277-4279. doi: 10.21037/jtd.2017.10.22. No abstract available.

16.

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.

Del Gobbo A, Morotti A, Colombo AE, Vaira V, Ercoli G, Pesenti C, Bonaparte E, Guerini-Rocco E, Di Cristofori A, Locatelli M, Palleschi A, Ferrero S.

Med Oncol. 2017 Dec 1;35(1):2. doi: 10.1007/s12032-017-1062-7.

PMID:
29209838
17.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.

Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.

J Thorac Oncol. 2017 Nov;12(11):1654-1663. doi: 10.1016/j.jtho.2017.07.031. Epub 2017 Aug 14.

18.

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.

Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.

19.

High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role.

Ravenda PS, Zampino MG, Guerini-Rocco E, Chiocca S, Dell'Acqua V, Trovato C, Biffi R, Ribero D, Spada F, Cella CA, Fazio N.

Ann Oncol. 2017 May 1;28(5):1160. doi: 10.1093/annonc/mdx032. No abstract available.

PMID:
28453691
20.

Circulating and tissue biomarkers in early-stage non-small cell lung cancer.

Fumagalli C, Bianchi F, Raviele PR, Vacirca D, Bertalot G, Rampinelli C, Lazzeroni M, Bonanni B, Veronesi G, Fusco N, Barberis M, Guerini-Rocco E.

Ecancermedicalscience. 2017 Jan 31;11:717. doi: 10.3332/ecancer.2017.717. eCollection 2017.

21.

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.

Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F.

Pharmacol Res. 2017 Mar;117:406-415. doi: 10.1016/j.phrs.2017.01.003. Epub 2017 Jan 12. Review.

PMID:
28089942
22.

Recurrent NAB2-STAT6 gene fusions and oestrogen receptor-α expression in pulmonary adenofibromas.

Fusco N, Guerini-Rocco E, Augello C, Terrasi A, Ercoli G, Fumagalli C, Vacirca D, Braidotti P, Parafioriti A, Jaconi M, Runza L, Ananthanarayanan V, Pagni F, Bosari S, Barberis M, Ferrero S.

Histopathology. 2017 May;70(6):906-917. doi: 10.1111/his.13165. Epub 2017 Feb 24.

PMID:
28072477
23.

The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Marchiò C, Geyer FC, Ng CK, Piscuoglio S, De Filippo MR, Cupo M, Schultheis AM, Lim RS, Burke KA, Guerini-Rocco E, Papotti M, Norton L, Sapino A, Weigelt B, Reis-Filho JS.

J Pathol. 2017 Feb;241(3):405-419. doi: 10.1002/path.4837. Epub 2016 Dec 26.

24.

Hibernation in Unusual Places: A Pure Typical Hibernoma of the Breast.

Runza L, Blundo C, Guerini-Rocco E, Forno I, Fusco N.

Breast J. 2017 Jan;23(1):104-105. doi: 10.1111/tbj.12694. Epub 2016 Oct 31. No abstract available.

PMID:
27797127
25.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.

26.

Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.

Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S, Ng CK, Pareja F, Wen HY, Hodi Z, Schnitt SJ, Rakha EA, Ellis IO, Norton L, Weigelt B, Reis-Filho JS.

Mod Pathol. 2017 Jan;30(1):69-84. doi: 10.1038/modpathol.2016.161. Epub 2016 Oct 7.

27.

Rediscovering Secondary Tumors of the Prostate in the Molecular Era.

Fusco N, Sciarra A, Guerini-Rocco E, Marchiò C, Vignani F, Colombo P, Ferrero S.

Adv Anat Pathol. 2016 May;23(3):170-9. doi: 10.1097/PAP.0000000000000115. Review.

PMID:
27058245
28.

The Genomic Landscape of Male Breast Cancers.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.

Clin Cancer Res. 2016 Aug 15;22(16):4045-56. doi: 10.1158/1078-0432.CCR-15-2840. Epub 2016 Mar 9.

29.

Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Guerini-Rocco E, Piscuoglio S, Ng CK, Geyer FC, De Filippo MR, Eberle CA, Akram M, Fusco N, Ichihara S, Sakr RA, Yatabe Y, Vincent-Salomon A, Rakha EA, Ellis IO, Wen YH, Weigelt B, Schnitt SJ, Reis-Filho JS.

J Pathol. 2016 Apr;238(5):677-88. doi: 10.1002/path.4691.

30.

Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis.

Monfardini L, Varano GM, Foà R, Della Vigna P, Bonomo G, Bertani E, Guerini-Rocco E, Spada F, Orsi F.

Cardiovasc Intervent Radiol. 2016 Jun;39(6):948-52. doi: 10.1007/s00270-015-1284-z. Epub 2015 Dec 29.

PMID:
26714693
31.

The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations.

Fusco N, Guerini-Rocco E, Del Gobbo A, Franco R, Zito-Marino F, Vaira V, Bulfamante G, Ercoli G, Nosotti M, Palleschi A, Bosari S, Ferrero S.

PLoS One. 2015 Dec 16;10(12):e0144923. doi: 10.1371/journal.pone.0144923. eCollection 2015.

32.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.

Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839.

33.

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M.

J Clin Oncol. 2015 Nov 20;33(33):3945-52. doi: 10.1200/JCO.2015.61.4743. Epub 2015 Sep 14.

34.

The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.

Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchiò C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS.

J Pathol. 2015 Oct;237(2):166-78. doi: 10.1002/path.4566. Epub 2015 Jul 29.

35.

Are acinic cell carcinomas of the breast and salivary glands distinct diseases?

Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, Edelweiss M, De Mattos-Arruda L, Wen HY, Rakha EA, Ellis IO, Rubin BP, Weigelt B, Reis-Filho JS.

Histopathology. 2015 Oct;67(4):529-37. doi: 10.1111/his.12673. Epub 2015 Mar 23.

36.

The birth of an adenoid cystic carcinoma.

Fusco N, Guerini-Rocco E, Schultheis AM, Badve SS, Reis-Filho JS, Weigelt B.

Int J Surg Pathol. 2015 Feb;23(1):26-7. doi: 10.1177/1066896914548795. Epub 2014 Sep 3. No abstract available.

37.

The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.

Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S, Ferrero S.

J Thorac Oncol. 2014 Nov;9(11):1656-61. doi: 10.1097/JTO.0000000000000316.

38.

Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions.

Atienza-Amores M, Guerini-Rocco E, Soslow RA, Park KJ, Weigelt B.

Gynecol Oncol. 2014 Aug;134(2):410-8. doi: 10.1016/j.ygyno.2014.05.017. Epub 2014 May 27. Review.

PMID:
24875120
39.

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS, King TA.

Clin Cancer Res. 2014 May 1;20(9):2326-37. doi: 10.1158/1078-0432.CCR-13-2267. Epub 2014 Mar 14.

40.

Dynamic retention of Ero1alpha and Ero1beta in the endoplasmic reticulum by interactions with PDI and ERp44.

Otsu M, Bertoli G, Fagioli C, Guerini-Rocco E, Nerini-Molteni S, Ruffato E, Sitia R.

Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):274-82.

PMID:
16677073

Supplemental Content

Loading ...
Support Center